Trial Profile
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Lung cancer; Malignant melanoma; Renal cell carcinoma; Solid tumours
- Focus Therapeutic Use
- 26 Feb 2024 Status changed from active, no longer recruiting to completed.
- 27 May 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 12 Jun 2019 Planned primary completion date changed from 1 Jan 2020 to 1 Dec 2019.